Pulmonx Corp
NASDAQ:LUNG

Watchlist Manager
Pulmonx Corp Logo
Pulmonx Corp
NASDAQ:LUNG
Watchlist
Price: 1.85 USD -3.14% Market Closed
Market Cap: $76.3m

Net Margin

-61.9%
Current
Improving
by 19.7%
vs 3-y average of -81.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-61.9%
=
Net Income
$-56.8m
/
Revenue
$91.7m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-61.9%
=
Net Income
$-56.8m
/
Revenue
$91.7m

Peer Comparison

Country Company Market Cap Net
Margin
US
Pulmonx Corp
NASDAQ:LUNG
76.3m USD
Loading...
JP
Hoya Corp
TSE:7741
8.7T JPY
Loading...
CH
Alcon AG
SIX:ALC
31.5B CHF
Loading...
US
Medline Inc
NASDAQ:MDLN
37.3B USD
Loading...
DK
Coloplast A/S
CSE:COLO B
122.5B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
12.2B USD
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
4.8B GBP
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
44B CNY
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
6B USD
Loading...
CH
Ypsomed Holding AG
SIX:YPSN
4.6B CHF
Loading...
KR
HLB Inc
KOSDAQ:028300
7.5T KRW
Loading...

Market Distribution

Lower than 82% of companies in the United States of America
Percentile
18th
Based on 15 072 companies
18th percentile
-61.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Pulmonx Corp
Glance View

Market Cap
76.3m USD
Industry
Health Care

Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

LUNG Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-61.9%
=
Net Income
$-56.8m
/
Revenue
$91.7m
What is Pulmonx Corp's current Net Margin?

The current Net Margin for Pulmonx Corp is -61.9%, which is above its 3-year median of -81.6%.

How has Net Margin changed over time?

Over the last 3 years, Pulmonx Corp’s Net Margin has increased from -111% to -61.9%. During this period, it reached a low of -111% on Sep 30, 2022 and a high of -61.9% on Sep 30, 2025.

Back to Top